STUTTGART, Germany--(BUSINESS WIRE)--Oct. 5, 2005--
218-patient study indicates Microcyn(TM) Technology superior in microbial load reduction, healing time, surgical dehiscence and adverse side effects as compared to povidone iodine (10%). Oculus Innovative Sciences, Inc. announced that Dr. Luca Dalla Paola, a surgeon with the diabetic foot unit of the Abano Terme Hospital in Italy, recently presented the results of a 218-patient controlled clinical study that assessed the safety and efficacy of Microcyn(TM) Technology in treating diabetic foot ulcers as compared to povidone iodine (10%) antiseptic, which is often used as the "standard care" in treatment of open wounds.
